Protalex, Inc. (PRTX) To Present Findings From U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients At The 2014 EULAR Annual European Congress Of Rheumatology
5/15/2014 8:54:32 AM
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB: PRTX), a clinical-stage biopharmaceutical company, today announced that results from Cohorts 1-4 of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study) will be highlighted in a poster presentation at EULAR’s Annual European Congress of Rheumatology to be held in Paris, June 11-14, 2014. PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The abstract is available on EULAR’s website and on the Company’s website at www.protalex.com.
Help employers find you! Check out all the jobs and post your resume.
comments powered by